CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.27BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.8160xvs all stocks
52-Week Change
38.50%vs all stocks
Market Capitalization
1.27BUSDvs all stocks (USD)
Enterprise Value
812.80MUSDvs all stocks (USD)
Forward P/E
-5.62xvs Biotechnology peers
Price to Book (MRQ)
2.74xvs Biotechnology peers
Enterprise to EBITDA
-4.03xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-26.14%vs Biotechnology peers
Return on Equity (TTM)
-41.01%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-201.83MUSDvs all stocks (USD)
Net Income (TTM)
-185.36MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-134.85MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-76.95MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-155.60MUSDvs all stocks (USD)
Pre-tax Income
-137.73MUSDFY2025 · Dec 31, 2025Income Tax Expense
217.00KUSDFY2025 · Dec 31, 2025Net Income
-137.95MUSDFY2025 · Dec 31, 2025EBIT
-155.60MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-155.50MUSDFY2025 · Dec 31, 2025Research & Development
125.10MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
30.51MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
17.87MUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.52USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.52USDFY2025 · Dec 31, 2025Basic Shares Outstanding
54.68MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
54.68MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-137.95MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-122.88MUSDFY2025 · Dec 31, 2025Free Cash Flow
-123.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
96.69MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-137.95MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
105.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
15.01MUSDFY2025 · Dec 31, 2025Other Non-cash Items
895.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-932.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-280.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-318.17MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-318.45MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
29.50MUSDFY2025 · Dec 31, 2025Shares Outstanding
65.55MSharesUpdated Sep 27, 2026Float Shares
36.90MSharesUpdated Sep 27, 2026Shares Short
11.19MSharesUpdated Sep 27, 2026Short Ratio
22.39daysvs all stocks
Short % of Shares Outstanding
23.56%vs all stocks
% Held by Insiders
10.07%vs all stocks
% Held by Institutions
107.61%vs all stocks
Total Cash (MRQ)
497.26MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.51USDUpdated Sep 27, 2026Total Debt (MRQ)
1.16MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0025xvs Biotechnology peers
Current Ratio (MRQ)
11.59xvs Biotechnology peers
Book Value per Share (MRQ)
7.11USDUpdated Sep 27, 2026Total Assets
430.99MUSDvs all stocks (USD)
Total Current Assets
422.05MUSDFY2025 · Dec 31, 2025Total Liabilities
29.54MUSDFY2025 · Dec 31, 2025Total Non-current Assets
8.94MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
593.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
28.95MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
96.69MUSDFY2025 · Dec 31, 2025Other Short-term Investments
318.12MUSDFY2025 · Dec 31, 2025Accounts Payable
7.79MUSDFY2025 · Dec 31, 2025Short-term Debt
1.12MUSDFY2025 · Dec 31, 2025Long-term Debt
593.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-358.97MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
401.45MUSDvs all stocks (USD)
52-Week Low
11.81USDUpdated Sep 27, 202652-Week High
30.99USDUpdated Sep 27, 202652-Week Change
38.50%vs all stocks
Beta
-0.8160xvs all stocks
50-Day MA
24.76USDUpdated Sep 27, 2026200-Day MA
21.32USDUpdated Sep 27, 2026Avg 10-Day Volume
662.97KSharesUpdated Sep 27, 2026Avg 30-Day Volume
549.11KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-3.07USDUpdated Sep 27, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.57
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Market cap is $1.27B, above the global median of $1.18BNotable
Market cap (USD): 1,271,182,062Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Immatics N.V.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Jiangsu Yahong Meditech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Damora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Akums Drugs & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Yizhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Xianju Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Changzhou Qianhong Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Integra LifeSciences Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Celltrion Pharm, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Hisun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule